Abstract
SM22α is a shape change and transformation sensitive 22 kDa actin-binding protein of the calponin family. It is ubiquitous to vascular and visceral smooth muscle, and is an early marker of smooth muscle differentiation. It is also present in fibroblasts, and some epithelium. SM22α may be involved in calcium-independent smooth muscle contraction. Recent evidence suggests that disruption of SM22α induces vascular inflammation and is involved in osteochondrogenesis in arterial diseases. This is consistent with activation of NF-κB signaling, where NF-κB activity is upregulated in vascular injury. High expression of SM22α inhibits cell proliferation in VSMCs and in injured arteries. SM22α acts as a tumor suppressor. Loss of its expression is an early event in cell transformation and the development of some tumors, coinciding with cellular plasticity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Cardiovascular & Hematological Disorders-Drug Targets
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
